Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987367 | 0.88 | — | — | |
| SCHEMBL17135306 | 0.86 | ENPP2 (0.43) | ENPP2LPAR2FBP1ALDH1A1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27763541 | 0.86 | FBP1 (0.48) | ENPP2LPAR2FBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18632674 | 0.86 | FBP1 (0.48) | ENPP2LPAR2FBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17135204 | 0.83 | ENPP2 (0.48) | ENPP2LPAR2FBP1ALDH1A1SMN1; SMN2 | |
| Dodecane SCHEMBL9803677 | 0.81 | ENPP2 (0.57) | ENPP2LPAR2ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL7329017 | 0.79 | CHRM2 (0.43) | ENPP2LPAR2FBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14515961 | 0.78 | ENPP2 (0.43) | ENPP2LPAR2FBP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14515947 | 0.78 | ENPP2 (0.43) | ENPP2LPAR2FBP1ALDH1A1SMN1; SMN2 | |
| Ether SCHEMBL20767714 | 0.77 | ENPP2 (0.42) | ENPP2LPAR2ALDH1A1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | ENPP2 505/4885LPAR2 2377/4885FBP1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.